Hans has a proven track record as a strategy‑driven business leader, known for delivering sustainable growth, leading complex organizations, and building energized, high‑performance teams.
Hans previously held senior leadership roles at Aspen Pharmacare and Biosynth, where he successfully scaled life‑sciences and manufacturing businesses across multiple international markets. His experience spans commercial leadership, operational excellence, strategic partnerships, and business transformation. Hans’s appointment reinforces InnoCore’s mission: “Delivering Long‑Acting Injectable Medicines for Improved Patient Health & Convenience.” With the rapid global expansion of biologics and peptide therapeutics, demand for advanced long‑acting injectable (LAI) drug delivery technologies is growing. InnoCore’s ambition—to become the Go‑To Partner for LAI Development of Biologics and Peptides—remains central to the company’s long‑term strategy.
A Leader for InnoCore’s Next Growth Phase, Hans will oversee strategic execution across:
– Expansion of global partnerships with biotech and pharma companies
– Acceleration of InnoCore’s proprietary LAI technology platform
– Driving innovation toward clinical and commercial success for customers
– Strengthening operational and development capabilities